|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/12/21 Obalon Therapeutics Inc. 10-K 12/31/20 83:8.4M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 937K
2: EX-10.32 Material Contract HTML 32K
3: EX-10.34 Material Contract HTML 32K
4: EX-21.1 Subsidiaries List HTML 24K
5: EX-23.1 Consent of Expert or Counsel HTML 24K
6: EX-23.2 Consent of Expert or Counsel HTML 24K
7: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
8: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
16: R1 Document and Entity Information HTML 66K
17: R2 Consolidated Balance Sheets HTML 98K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 32K
19: R4 Consolidated Statements of Operations and HTML 75K
Comprehensive Loss
20: R5 Consolidated Statements of Stockholders' Equity HTML 85K
(Deficit)
21: R6 Consolidated Statements of Cash Flows HTML 113K
22: R7 Organization and Basis of Presentation HTML 35K
23: R8 Summary of Significant Accounting Policies HTML 89K
24: R9 Fair Value Measurements HTML 154K
25: R10 Net Loss per Share HTML 51K
26: R11 Balance Sheet Details HTML 111K
27: R12 Debt HTML 34K
28: R13 Stock-Based Compensation HTML 177K
29: R14 Stockholders' Equity HTML 54K
30: R15 Income Taxes HTML 136K
31: R16 Commitments and Contingencies HTML 54K
32: R17 Variable Interest Entity HTML 28K
33: R18 Restructuring Charges HTML 58K
34: R19 Subsequent Events HTML 33K
35: R20 Summary of Significant Accounting Policies HTML 146K
(Policies)
36: R21 Summary of Significant Accounting Policies HTML 57K
(Tables)
37: R22 Fair Value Measurements (Tables) HTML 153K
38: R23 Net Loss per Share (Tables) HTML 53K
39: R24 Balance Sheet Details (Tables) HTML 116K
40: R25 Stock-Based Compensation (Tables) HTML 181K
41: R26 Stockholders' Equity (Tables) HTML 34K
42: R27 Income Taxes (Tables) HTML 137K
43: R28 Commitments and Contingencies (Tables) HTML 43K
44: R29 Restructuring Charges (Tables) HTML 59K
45: R30 Organization and Basis of Presentation - HTML 52K
Additional Information (Detail)
46: R31 Summary of Significant Accounting Policies - HTML 49K
Additional Information (Detail)
47: R32 Summary of Significant Accounting Policies - HTML 37K
Concentration Risk (Details)
48: R33 Summary of Significant Accounting Policies - HTML 33K
Estimated Useful Lives (Details)
49: R34 Fair Value Measurements - Schedule of Assets and HTML 44K
Liabilities Measured at Fair Value on Recurring
Basis (Details)
50: R35 Fair Value Measurements - Schedule of Fair Value HTML 38K
Assumptions (Details)
51: R36 Fair Value Measurements - Schedule of Liabilities HTML 32K
Measured at Fair Value (Details)
52: R37 Net Loss per Share - Schedule of Computation of HTML 36K
Basic and Diluted Net Loss Per Share of Common
Stock (Details)
53: R38 Net Loss per Share - Schedule of Anti-Dilutive HTML 32K
Common Stock Equivalents Excluded from the
Calculation of Diluted Net Loss Per Share
(Details)
54: R39 Balance Sheet Details - Schedule of Inventory HTML 35K
(Details)
55: R40 Balance Sheet Details - Schedule of Other Current HTML 32K
Assets (Details)
56: R41 Balance Sheet Details - Schedule of Property and HTML 50K
Equipment, Net (Details)
57: R42 Balance Sheet Details - Schedule of Other Current HTML 39K
Liabilities (Details)
58: R43 Balance Sheet Details - Insurance Refund (Details) HTML 26K
59: R44 Debt (Details) HTML 79K
60: R45 Stock-Based Compensation - Additional Information HTML 71K
(Details)
61: R46 Stock-Based Compensation - Summary of Stock-Based HTML 33K
Compensation (Details)
62: R47 Stock-Based Compensation - Summary of Fair Value HTML 38K
of Stock Options for Employees was Estimated using
Black-Scholes Option Pricing Model (Details)
63: R48 Stock-Based Compensation - Summary of Stock Option HTML 71K
Transactions (Details)
64: R49 Stock-Based Compensation - Summary of Restricted HTML 56K
Stock Awards and Restricted Stock Units (Details)
65: R50 Stockholders' Equity - Additional Information HTML 156K
(Details)
66: R51 Stockholders' Equity - Schedule of Common Stock HTML 36K
Reserved for Future Issuance (Details)
67: R52 Income Taxes - Income Tax Provision (Benefit) HTML 46K
(Details)
68: R53 Income Taxes - Effective Income Tax Rate HTML 37K
Reconciliation (Details)
69: R54 Income Taxes - Deferred Tax Assets and Liabilities HTML 46K
(Details)
70: R55 Income Taxes - Additional Information (Details) HTML 47K
71: R56 Income Taxes - Roll Forward of Unrecognized Tax HTML 33K
Benefits (Details)
72: R57 Commitments and Contingencies - Additional HTML 65K
Information (Details)
73: R58 Commitments and Contingencies - Schedule of Future HTML 41K
Minimum Annual Lease Payments (Details)
74: R59 Commitments and Contingencies - Schedule of Future HTML 30K
Minimum Annual Lease Payments, Lease Liability,
Classified (Details)
75: R60 Variable Interest Entity (Details) HTML 28K
76: R61 Restructuring Charges - Additional Information HTML 54K
(Details)
77: R62 Restructuring Charges - Restructuring and Related HTML 31K
Costs (Details)
78: R63 Restructuring Charges - Restructuring Charges HTML 33K
(Details)
79: R64 Restructuring Charges - Restructuring Charge HTML 31K
Reserve Balance (Details)
80: R65 Subsequent Events (Details) HTML 50K
82: XML IDEA XML File -- Filing Summary XML 145K
81: EXCEL IDEA Workbook of Financial Reports XLSX 109K
10: EX-101.INS XBRL Instance -- obln-20201231 XML 2.08M
12: EX-101.CAL XBRL Calculations -- obln-20201231_cal XML 169K
13: EX-101.DEF XBRL Definitions -- obln-20201231_def XML 556K
14: EX-101.LAB XBRL Labels -- obln-20201231_lab XML 1.45M
15: EX-101.PRE XBRL Presentations -- obln-20201231_pre XML 976K
11: EX-101.SCH XBRL Schema -- obln-20201231 XSD 165K
83: ZIP XBRL Zipped Folder -- 0001558370-21-002923-xbrl Zip 180K
Exhibit 31.2
Obalon Therapeutics, Inc.
Certification of Chief Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Nooshin Hussainy, certify that:
| 1. | I have reviewed this Annual Report on Form 10-K of Obalon Therapeutics, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| (c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| (d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| |
Date: March 12, 2021 | /s/ Nooshin Hussainy |
| |
| Chief Financial Officer |
| (Principal Financial Officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/12/21 | 8-K | ||
| For Period end: | 12/31/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/24/23 ReShape Lifesciences Inc. 424B5 2:487K Toppan Merrill/FA 11/09/22 ReShape Lifesciences Inc. 424B5 2:506K Toppan Merrill/FA 9/21/21 ReShape Lifesciences Inc. 424B3 1:199K Toppan Merrill/FA 9/03/21 ReShape Lifesciences Inc. S-3 5:337K Toppan Merrill/FA 9/03/21 ReShape Lifesciences Inc. S-3 5:461K Toppan Merrill/FA 4/09/21 ReShape Lifesciences Inc. S-4/A 89:13M Toppan Merrill/FA 3/30/21 ReShape Lifesciences Inc. S-4 25:18M Toppan Merrill/FA |